Bristol Myers director receives 3,996 deferred share units
Bristol Myers Squibb director Paula A. Price reported receiving 3,996.367 Deferred Share Units on February 1, 2026 at an indicated value of $55.05 per unit.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Bristol Myers Squibb director Paula A. Price reported receiving 3,996.367 Deferred Share Units on February 1, 2026 at an indicated value of $55.05 per unit. Following this award, she beneficially owns 25,498.163 Deferred Share Units, held directly.
Each Deferred Share Unit is designed to convert into one share of Bristol Myers Squibb common stock upon settlement. The units become settleable when Price ceases to be a director or at a future date she previously specified, and include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Share Units | 3,996.367 | $55.05 | $220K |
Footnotes (2)
- F1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
- F2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Bristol Myers Squibb (BMY) disclose for Paula A. Price?
AI-generated analysis. How Rhea-AI works. Not financial advice.